CClinicalTrials.gg
CompletedNCT03413917Updated Jan 26, 2026

Exploration and Determination of Genomic Markers Predictive of Uterine Atony

An observational study in Uterine Atony, sponsored by Baylor Research Institute. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Baylor Research Institute · Observational

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
21
Ages
18 Years and older
Sex
Female
01

Study summary

The primary objective of this study is to determine whether there are markers in the tissue of atonic uteri, and in the patients' plasma that would help identify patients likely to suffer postpartum hemorrhage due to uterine atony. We also will attempt to identify the cause(s) of uterine atony that might suggest mechanisms to prevent and manage it.

Read the detailed description

Patient will be recruited from those admitted to our Labor and Delivery unit. Ten women will be the control subjects, and these will be selected from patients who are admitted for scheduled cesarean delivery. Ten women will be selected from women who develop uterine atony either following cesarean delivery, or postpartum patients who delivered vaginally but subsequently required surgical management of uterine atony (hysterectomy or uterine saving surgery). From each patient a small amount of uterine muscle will be excised and placed in a fixative, preservative transport medium. Ten cubic centimeters of blood will be drawn from each patient to accompany the tissue. The tissue and blood will be processed and analyzed to identify differences in the tissue and plasma of messenger RNA, micro RNA, long non-coding RNA, and DNA methylation in normal and atonic uterine patients. Statistical analysis of these markers will be performed to determine whether there are significant differences in their expression. It is hoped that differences will be discovered that may be used diagnostically to predict uterine atony, and differences that may suggest the etiology of uterine atony.

02

Conditions studied

  • Uterine Atony

Browse trials for

Keywords

  • genomic markers
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients recruited for the study will be pregnant women, 18 years of age or older who are laboring in Labor and Delivery, or who plan to have a scheduled cesarean section.

Inclusion criteria

  • 18 years of age or older
  • female
  • pregnancy over 23 weeks gestation

Exclusion criteria

Exclusion Criteria:

  • under 18 years of age
  • prisoners
  • non-female sex
  • cannot provide informed consent
04

Study design

Observational model
Other
Time perspective
Other
Enrollment
21 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Control group

    patients who are admitted for repeat cesarean delivery with bilateral tubal ligation who do not develop uterine atony

    Other: Analysis of genomic markers in uterine atony

  • Study group

    Patients who develop uterine atony either during cesarean delivery or who require surgical management of atony after delivery

    Other: Analysis of genomic markers in uterine atony

Interventions

  • OtherAnalysis of genomic markers in uterine atony

    No intervention will be performed. We will be analyzing tissue and blood samples only to identify potential association of genomic markers with uterine atony.

05

What researchers measure

Primary outcomes

  1. Identification of genomic markers that can predict uterine atony

    To extract RNA from serum and uterine tissue samples and use Next Generation miRNA Sequencing followed by quantification of serum miRNA and miRNA isoform expression using TaqMan miRNA assays and NanoString.

    Time frame: 6-12 months

  2. Identification of genomic markers that can predict uterine atony (2)

    Following extraction of miRNA, to use Optical Liquid Stamping technology to analyze various miRNA isoforms in the uterine tissue and serum of subjects with normal uteri compared to atonic uteri.

    Time frame: 6-12 months

  3. Identification of genomic markers that can predict uterine atony (3)

    To isolate DNA using QIAAMp DNA mini kits from uterine tissue and serum samples from subjects with atonic uteri and normal uteri and to then sequence the DNA using HiSeq Genome Analyzer. We will identify the sequence reads using Illumina base-calling software and analyze them using Zymo research proprietary analysis pipeline to identify differences in genomic expression in subjects with normal uteri compared to atonic uteri.

    Time frame: 6-12 months

06

Study locations

1 site
  • Baylor Univeristy Medical Center
    Dallas, Texas 75246, United States
07

References and documents

Publications

  • Toiyama Y, Okugawa Y, Tanaka K, Araki T, Uchida K, Hishida A, Uchino M, Ikeuchi H, Hirota S, Kusunoki M, Boland CR, Goel A. A Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients With Ulcerative Colitis-Associated Colorectal Cancer. Gastroenterology. 2017 Dec;153(6):1634-1646.e8. doi: 10.1053/j.gastro.2017.08.037. Epub 2017 Aug 25. PubMed 28847750 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03413917
Lead sponsor
Baylor Research Institute
Responsible party
Sponsor
First posted
Jan 29, 2018
Start date
Feb 2, 2018
Primary completion
Jul 1, 2020
Completion
Jul 1, 2020
Last update
Jan 26, 2026

Study contacts

Jack Stecher, MD
principal investigator · Baylor Univeristy Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion